Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy
| Autor: | H Brath, Giovanni Bader, Päivi M. Paldánius, W M Kolaczynski, Peter M. Nilsson |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Pyrrolidines endocrine system diseases Endocrinology Diabetes and Metabolism India 030209 endocrinology & metabolism Adamantane 030204 cardiovascular system & hematology 03 medical and health sciences Middle East 0302 clinical medicine Sex Factors Diabetes mellitus Internal medicine Post-hoc analysis Nitriles Internal Medicine medicine Humans Hypoglycemic Agents Glycemic Aged Glycated Hemoglobin Vildagliptin Dipeptidyl-Peptidase IV Inhibitors business.industry Asia Eastern Age Factors Type 2 Diabetes Mellitus Middle Aged medicine.disease Metformin Surgery Europe Latin America Treatment Outcome Diabetes Mellitus Type 2 Drug Therapy Combination Female Original Article Metabolic syndrome business Body mass index Pioglitazone medicine.drug |
| Zdroj: | Nutrition & Diabetes |
| ISSN: | 2044-4052 |
| Popis: | Objective: This post-hoc analysis of the EDGE (Effectiveness of Diabetes control with vildaGliptin and vildagliptin/mEtformin) study assessed inter-regional differences in baseline characteristics and response to treatment intensification with dual oral antidiabetes drugs (OADs) in patients with type 2 diabetes mellitus (T2DM). Methods: Patients with T2DM inadequately controlled with first-line monotherapy were assigned to receive a dipeptidyl peptidase-4 (DPP-4) inhibitor, vildagliptin, or comparator OADs as add-on dual therapy. The primary effectiveness end point (PEP) was achieving glycated hemoglobin (HbA1c) reduction >0.3% without hypoglycemia, peripheral edema, discontinuation owing to gastrointestinal events or weight gain ⩾5% at 12 months. The secondary effectiveness end point (SEP) was achieving HbA1c of Results: Baseline characteristics of patients (N=43 791), including mean HbA1c (8.2%), varied across regions. Baseline age (62.3 years) and T2DM duration (6.3 years) were greater in patients from Europe than those from India and the Middle East (age: 51.8 and 52.1 years; T2DM duration: 4.3 and 4.2 years, respectively). The probability of achieving PEP with dual therapy was higher in India (odds ratio (OR): 1.5), Latin America (OR: 1.2) and Middle East (OR: 2.0) than in Europe (OR: 0.8) and East Asia (OR: 0.3). Achievement of SEP in patients receiving dual therapy was greater in Latin America (OR: 1.7) and Middle East (OR: 1.7). Vildagliptin add-on therapy allowed more patients to achieve SEP across regions. Women aged ⩾45 years less often attained glycemic target (HbA1cP=0.037). Conclusions: Baseline HbA1c and T2DM duration differed considerably across all regions. Treatment intensification with second OAD, particularly with a DPP-4 inhibitor vildagliptin, resulted in good treatment response without tolerability issues despite delayed intensification of failing monotherapy across regions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|